

RECEIVED  
CENTRAL FAX CENTER

Application No. 09/171,697 - - - - 2

DEC 07 2004

Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-10 (canceled).

Claim 11 (previously presented): The compound of claim 12 wherein the compound is selected from the group consisting of (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline, (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline methyl ester, and N-phenyl, N-[2-methoxy]phenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline.

Claim 12 (currently amended): A compound for treating ~~withdrawal syndromes manifested in a patient suffering withdrawal symptoms and/or withdrawal-induced brain damage~~ and having the formula (I):



(I)

a tautomer thereof, a pharmacologically acceptable ester, amide, salt, ether, or an acid addition salt thereof;

wherein R¹ represents hydrogen or an alkyl group of 1 to 3 carbon atoms;

Application No. 09/171,697 - - - - 3

$R^2$  and  $R^3$  each independently represent phenyl which may be unsubstituted or alkoxy substituted one or more times with alkoxy containing 1 to 3 carbon atoms, wherein each of the  $R^2$  and  $R^3$  substituents can be the same or different; and X represents halogen and each of the 5, 7, substituents can be the same or different.

Claim 13 (original): A compound of claim 12 wherein each of the X substituents is chloro,  $R^1$  is hydrogen, and  $R^2$  and  $R^3$  each is a phenyl group.

Claim 14 (original): A compound of claim 12 wherein each of the X substituents is chloro,  $R^1$  is an alkyl group having 1 to 3 carbon atoms, and  $R^2$  and  $R^3$  each is a phenyl group.

Claim 15 (original): A compound of claim 12 wherein each of the X substituents is chloro,  $R^1$  is hydrogen, one of  $R^2$  and  $R^3$  is an unsubstituted phenyl group and the other is phenyl having an alkoxy substituent having 1 to 3 carbon atoms.

Claim 16 (original): A method of preparing a compound of claim 12 comprising the steps of:

- a) reacting 3,5-dichloroaniline and dimethyl acetylenedicarboxylate to form dimethylanilinofumarate;
- b) cyclizing the dimethylanilinofumarate with diphenyl ether to form 4(1H)-quinolone-2-carboxylate;
- c) aminating the 4(1H)-quinolone-2-carboxylate with chlorosulphonyl isocyanate in acetonitrile to form a 4-aminated derivative thereof; and
- d) acylating the 4-aminated derivative with diphenyl carbamoyl chloride to form (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline methyl ester.

Claim 17 (original): The method of claim 16 further including the step of:

- e) hydrolyzing the (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline methyl ester to (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline.


Claim 18 (original): The product of the method of claim 16.

Claim 19 (original): The product of the method of claim 17.

Claim 20 (canceled).

Application No. 09/171,697 - - - - - 4

Claim 21 (currently amended): A method for treating a patient to prevent or ameliorate neuroexcitability disorders comprising administering to a patient in need of such treatment an effective amount of a an-antagonist compound of claim 12 having the formula (I):



(I)

a tautomer thereof, a pharmacologically acceptable ester, amide, salt, ether, or an acid addition salt thereof;

wherein R<sup>1</sup> represents hydrogen or an alkyl group of 1 to 3 carbon atoms;

R<sup>2</sup> and R<sup>3</sup> each independently represent phenyl which may be unsubstituted or alkoxy substituted one or more times with alkoxy containing 1 to 3 carbon atoms,

wherein each of the R<sup>2</sup> and R<sup>3</sup> substituents can be the same or different; and

X represents halogen and each of the 5, 7, substituents can be the same or different and exhibiting affinity for both the strychnine-insensitive glycine binding site on N-methyl-D-aspartate receptor and voltage dependent sodium channels.

Claim 22 (previously presented): The method of claim 21 wherein the compound is selected from the group consisting of N,N-diphenyl-substituted-4-ureido-5,7-dichloro-2-carboxy-quinoline, a tautomer thereof, a pharmacologically acceptable ester, amide, salt, ether and addition salt thereof.

Claim 23 (previously presented): The method of claim 21 wherein the compound is selected from the group consisting of (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline, (N,N-diphenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline methyl ester, and N-phenyl, N-[2-methoxy]phenyl)-4-ureido-5,7-dichloro-2-carboxy-quinoline.